Status:
COMPLETED
Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma
Lead Sponsor:
University of Utah
Conditions:
Melanoma (Skin)
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a phase II placebo-controlled intervention trial assessing aspirin (ASA) as a UV protectant in patients at risk for melanoma.
Detailed Description
While melanoma risk is largely genetically determined, exposure to ultraviolet (UV) radiation in sunlight is the major environmental risk factor. Although sunscreen use can reduce melanoma risk 2-fold...
Eligibility Criteria
Inclusion
- Must have at least 2 nevi (each \>5 mm diameter) not clinically suspicious for melanoma that can be biopsied.
- Must be older than age 18.
- Must be able to receive informed consent and sign an approved consent form that conforms to federal and institutional guidelines.
Exclusion
- The patient cannot speak / understand English or Spanish.
- The patient is pregnant or breastfeeding.
- The patient is a prisoner, critically or mentally ill, or otherwise incapacitated or considered vulnerable.
- The patient has history of allergic reaction to ASA.
- The patient has history of severe asthma.
- The patient has been taking ASA or any NSAID in the past 2 weeks.
- The patient has been taking a blood thinner in the past 2 weeks.
- The patient has history of bleeding disorder.
- The patient has history of peptic ulcer disease.
- The patient has had recent intense UV exposure in the past month.
Key Trial Info
Start Date :
July 25 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 19 2021
Estimated Enrollment :
95 Patients enrolled
Trial Details
Trial ID
NCT04066725
Start Date
July 25 2019
End Date
March 19 2021
Last Update
February 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, United States, 84112